Aligos Therapeutics (ALGS) Free Cash Flow (2019 - 2026)

Aligos Therapeutics has reported Free Cash Flow for 8 years, with the latest figure at -$23.1 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 10.61% year-over-year to -$23.1 million; the trailing twelve-month figure through Mar 2026 stood at -$84.7 million (down 7.37% YoY), and the FY2025 full-year result was -$82.5 million, down 2.02% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$23.1 million, down from -$21.7 million in the prior quarter.
• The five-year high for Free Cash Flow was -$13.6 million in Q2 2023, with the low at -$25.4 million in Q2 2022.
• Historically, Free Cash Flow has averaged -$20.3 million across 5 years, with a median of -$20.9 million in 2025.
• Annual changes were most pronounced in 2022 — Free Cash Flow jumped 55.38% — and 2024, when it tumbled 43.16%.
• Aligos Therapeutics' Free Cash Flow stood at -$16.9 million in 2022, then tumbled by 34.28% to -$22.7 million in 2023, then increased by 18.78% to -$18.4 million in 2024, then dropped by 18.16% to -$21.7 million in 2025, then decreased by 6.36% to -$23.1 million in 2026.
• The last three Free Cash Flow figures came in at -$23.1 million (Q1 2026), -$21.7 million (Q4 2025), and -$24.3 million (Q3 2025), per Business Quant data.